Saxagliptin plus dapagliflozin shows benefits

Adding a combination of DPP-4 and SGLT2 inhibitors to background metformin in poorly controlled type 2 diabetes patients achieves better results than adding either component alone,according to the results of a clinical trial.

More than 40% of poorly controlled patients receiving saxagliptin (SAXA) plus dapagliflozin (DAPA) achieved an A1C goal of <7%, with weight loss similar to DAPA alone and with very low hypoglycaemia risk, according to the results presented at  the conference of the European Association for the Study of Diabetes (EASD 2014) in Vienna .

In the 24-week, multicentre, randomised, double-blind, active-controlled trial, 534 adults with and A1C ≥8.0% and ≤12.0% received SAXA  5mg and DAPA 10mg once daily compared with SAXA plus placebo or DAPA plus placebo on